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Abstract 
Background: To determine the effect of ghrelin 
antagonist (D-Lys3) on plasma glucose, insulin 
resistance, serum testosterone and luteinizing 
hormone levels, on obese and type 2 diabetic mice.  
Methods: Fifty healthy BALB/c mice were divided 
into five groups. Mice in group II to V were fed 
high-fat diet for 4 weeks followed by intraperitoneal 
(IP) injection of streptozotocin to group IV and V to 
induce type 2 diabetes mellitus. Group I served as 
control.Groups II and III were obese and group IV 
and V were diabetic. Groups III and V were injected 
ghrelin antagonist IP for 6 days. Terminal 
intracardiac blood extraction was done and samples 
were analyzed for fasting plasma glucose, serum 
insulin, testosterone and luteinizing hormone. 
Insulin resistance was calculated by homeostatic 
model assessment for insulin resistance.  
Results: Plasma glucose level and insulin resistance 
decreased and serum testosterone and luteinizing 
hormone levels increased after using ghrelin 
antagonist in group III and V. 
Conclusion: Glucose level and insulin resistance 
were significantly decreased in obese and type 2 
diabetic mice after ghrelin antagonist 
administration. Whereas serum testosterone and 
luteinizing hormone levels were increased 
Key Words: Ghrelin  antagonist ,testosterone, 
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Introduction 
     Obesity is considered as the epidemic of the 
modern world. 1 The incidence of obesity has doubled 
in the past twenty years, which may be due to altered 
eating habits and sedentary life style. 2  It not only 
affects the quality of life by decreasing the general 
body performance, but also leads to the development 
of many metabolic disorders including diabetes 
mellitus, insulin resistance, fatty liver disease and 
atherosclerosis. 3   
   Type 2 diabetes mellitus is characterized by 
hyperglycemia, hyperinsulinemia and insulin 
resistance.More than 80 % cases of type 2 diabetes 
mellitus are obese. 4 Obesity leads to a decrease in 
expression and translocation of glucose transporter 
type 4 (GLUT4) in adipocytes. In addition there is also 
loss of tyrosine phosphatase activity leading to a loss 
of 80-90% of its function. 5 Normalization of body 
mass index leads to reversal of all these mechanisms 
leading to an improvement in efficacy of blood glucose 
control mechanisms. 6 
     It has been found that obesity directly and 
indirectly affects the male reproductive functions, 
leading to a decrease in the secretion of male sex 
hormone i.e. testosterone. 7 A variety of cytokines, 
adipokines and free fatty acids are secreted from 
adipocytes which directly affects the plasma androgen 
levels.8 The quantitative and qualitative efficacy of 
leydig cells is also decreased. There is decrease in the 
expression of glucose transporter type 3 (GLUT3) on 
leydig cells. In addition there is also decrease in its 
tyrosine phosphorylation activity leading to loss of its 
function.9  Obesity may also affect male reproductive 
system indirectly via insulin resistance. Insulin 
resistance and plasma testosterone levels are found to 
be in negative correlation with each other. 10 The 
mentioned effects may also be exerted through ghrelin 
hormone which is increased in obesity and type 2 
diabetes mellitus. 11  
     Ghrelin a 28-amino acid peptide hormone was 
discovered in 1999 from the stomach extracts of rats. 12 
It is a hunger stimulating hormone secreted from 
stomach and pancreas. Ghrelin receptors (G protein-
coupled receptors), are expressed in a number of 
tissues including pituitary, stomach, intestine, 
pancreas, thymus, gonads, thyroid, and heart.13 The 
wide expression of ghrelin receptors suggests that this 
hormone has diverse functions in different tissues. 
Ghrelin decreases the secretion of insulin from beta 
cells of pancreas in response to hyperglycemia (by 
decreasing the influx of calcium in the beta cells of 
pancreas secondary to hyperglycemia), leading to an 
increase in the plasma glucose levels. 14 D-Lys3 GHRP6 
(His-D-Lys-Trp-D-Phe-Lys-NH2) acts as ghrelin 
receptor antagonist. It acts on ghrelin receptor GHS-
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R1a and has been used in numerous studies. 
Administration of ghrelin receptor antagonist (D-Lys3 ) 
in normal and obese mice, leads to an increase in the 
secretion of insulin accompanied with decrease in 
blood glucose levels.15, 16   
     Ghrelin acts as a negative modulator of male 
reproductive system. It causes a decrease in number of 
leydig and sertoli cells in rats. 17 The high level of 
ghrelin is associated with a decrease in plasma 
testosterone and gonadotropin hormones (leutinizing 
hormone and follicle stimulating hormone.18 Ghrelin 
also acts upstream in hypothalamo- hypophyseal 
gonadal axis and reduces the pulse frequency of 
gonadotropin-releasing hormone (GnRH). 19 Ghrelin 
antagonist improves testosterone production in obese 
mice. 20 The mechanism involved is not clear. Ghrelin 
antagonist may act via luteinizing (LH) which in turn 
increases the secretion of testosterone. The purpose of 
this study was to identify the site of action of ghrelin 
antagonist in the hypophysial-gonadal axis, which is of 
clinical significance in obese and diabetic human male 
reproductive health. 
 
Materials and Methods 
    This study was conducted at Department of 
Physiology, Army Medical College, Rawalpindi, in 
collaboration with National Institute of Health (NIH), 
Islamabad, Pakistan. The study was approved by 
animal ethics committee of Army Medical  College, 
NUST and all animals received humane 
care.Streptozotocin (STZ) and ghrelin antagonist were 
purchased from Bioplus Fine Research Chemicals and 
Sigma Chemicals, USA respectively. Glucose was 
measured by GOD-POD method.Enzyme linked 
immunosorbent assay (ELISA) was used to measure 
serum insulin, serum testosterone and serum LH 
levels. 
    Five weeks old, 50 healthy BALB/c male mice were 
purchased from National Institute of Health, 
Islamabad. An average weight of mouse was 28.07 g ± 
0.1. Mice were divided into five equal groups. They 
were given free access to food and water. The room 
was well ventilated with controlled temperature range 
of 20-22°C and 12 hours light and dark cycles were 
maintained. After acclimatization the animals were 
randomly divided into five groups. Group 1 (control) 
was fed normal pellet diet, while group II-V were 
given high fat diet ad libitum (to induce obesity and 
insulin resistance) for 4 weeks. After 4 weeks, group 
IV and V were given intraperitoneal injections of 
streptozotocin 50mg/kg body weight for 5 days, as 
previously described to induce type 2 diabetes. STZ 
induces rapid and extensive degradation of cellular 
deoxyribonucleic acid (DNA) of beta cells of 
pancreas.21, 22 All the other groups were injected 
intraperitoneally with normal saline. Tail vein blood 
samples were used to measure (fasting) blood glucose 
levels and to confirm diabetes.  The blood glucose 
level >252 mg/dl was taken as the cut off value for 
confirming diabetes mellitus. 22 This was followed by 
intraperitoneal injection of ghrelin antagonist 10 
μmol/kg for 6 days in 9th week 23 to group III and V.  
On 62nd day , terminal blood sample was collected by 
intracardiac puncture. 24  The samples were stored at -
20o C for further analysis. The statistical significance of 
differences across the groups was determined by 
applying analysis of variance Post-hoc (ANOVA) 
followed by Tukey’s HSD to find the difference in 
various pairs of groups. P value < 0.05 was considered 
significant. 
 
Results 
     There was no significant difference in body weight 
of mice at the start of study (Table 1). The average 
weight of the mice was 28.07g ± 0.10.  There was 
continuous weight gain by the mice throughout the 
experiment.  Weight of the mice in obese group 
treated with ghrelin antagonist (group III) were 
significantly reduced compared with obese group II (p 
=0). Ghrelin antagonist treated diabetic group (group 
V) mice showed significant reduction in weight as 
compared with diabetic group IV (p = 0).  
 
Table1. Weight of BALB/c mice at start and end of 
experiment 
  
Weight of 
mice in grams 
 
 
Group I 
Control 
 
Group 
II 
Obese 
 
Group III 
Obese with 
ghrelin 
antagonist 
 
Group 
IV 
Diabet
-ic 
 
Group V 
Diabetic 
with 
ghrelin 
antagonist 
 
Start of 
experiment 
 
28.1± 
0.27 
 
28.09± 
0.45 
 
28.18± 0.21 
 
27.91± 
0.38 
 
28.07± 0.38 
 
End of 
Experiment 
 
32.81± 
1.56 
 
39 ± 
0.68 
 
36.7 ± 0.62 
 
41.2 ± 
1.48 
 
37.21± 0.37 
     There was no significant difference in the blood 
glucose level of different groups at the start of the 
experiment (Table 2). After 8 weeks of study i.e. on 
day 55, fasting blood glucose levels were significantly 
high in group IV and group V compared with the 
control (group I) (p = 0). There was no significant 
difference between other groups.At the end of the 
experiment blood glucose level in terminal blood 
samples showed that group II was significantly raised 
compared with the control and group III (p = 0) while 
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it was significantly low compared with group IV and 
group V ( p = 0 ). Group IV was significantly high 
compared with Group I and V (p = 0). Blood glucose 
level at the end of the experiment was significantly 
higher in Group V compared with the control (p = 0). 
Ghrelin antagonist significantly reduced the blood 
glucose levels in group III (p = 0) and Group V (p = 0) 
compared with group II and group IV respectively. 
 
Table 2. Fasting blood glucose, insulin and HOMA 
IR levels in BALB/c mice 
 
Blood 
parameters 
 
Group 
I 
n = 10 
 
Group 
II 
n = 10 
 
Group 
III 
n = 10 
 
Group 
IV 
n = 10 
 
Group 
V 
n = 10 
Initial Blood 
glucose level 
(mg/dl) 
97.2 ± 
11.87 
101.89 
± 16.07 
107.70 ± 
13.74 
105.90 
± 0.93 
109.67 ± 
17.25 
Blood 
glucose level 
at 8 weeks 
(mg/dl) 
100.2 ± 
9.59 
116 ± 
11.05 
118 ± 
10.91 
383.6 ± 
17.06 
395.67 ± 
20.73 
Blood 
glucose level 
in terminal 
samples 
(mg/dl) 
92.6 ± 
10.17 
169.9 ± 
9.8 
103 ± 
7.3 
488.8 ± 
17.19 
257.56 ± 
20.09 
 
Serum 
Insulin levels 
(µIU/ml) 
(terminal 
sample) 
2.17 ± 
0.10 
3.11 ± 
0.09 
3.43 ± 
0.14 
4.77 ± 
0.13 
5.07 ± 
0.13 
Insulin 
Resistance 
HOMA-IR 
(terminal 
sample) 
0.49 ± 
0.05 
1.29 ± 
0.09 
0.87 ± 
0.08 
5.75 ± 
0.22 
 
 
3.24 ± 
0.29 
 
     At the end of experiment fasting serum insulin 
levels were significantly high in group II, IV and V 
compared with control. There was no significant 
difference between group III and control.  In addition, 
insulin levels were significantly raised in ghrelin 
antagonist treated groups compared with their 
respective untreated groups.  The levels were 
significantly raised in obese group III and diabetic 
group V compared with obese group II (p = 0.001) and 
diabetic group IV (p = 0) respectively (Table 2). Insulin 
resistance (HOMA-IR) was decreased in ghrelin 
antagonist treated groups compared with untreated 
groups. HOMA-IR in group III was significantly low 
compared with group II (p = 0). Group V was 
significantly low compared with diabetic group IV (p 
= 0). 
     Levels of testosterone were increased in ghrelin 
antagonist treated groups. Although not reaching 
significant difference, the levels were 34.7% increased 
in group III compared with group II (p = 0.05).  
Testosterone levels in group V (72.5% increase) were 
significantly high (p = 0.006) compared with group IV. 
The levels of testosterone were significantly lower in 
all groups compared with the control group I (p < 
0.05).The levels of LH were significantly high in group 
III compared with group II (p = 0) and in group V 
compared with group IV (p = 0). The levels of 
luteinizing hormone was significantly lower in all 
other groups compared with the control group 1 (p = 
0).)Table 3) 
Table 3. Serum testosterone and luteinizing hormone 
levels in BALB/c mice at the end of the experiment 
Hormonal 
Profile 
Group I 
 
Group 
II 
Group 
III 
Group 
IV 
Group 
V 
Serum 
Testosterone 
pg/ml 
791.11 
± 
107.02 
434.35 
± 
82.80 
585.07 
 ± 
124.88 
268.19 
± 
132.19 
462.75 
± 
138.75 
Serum LH 
(mIU/ml) 
8.3± 
0.45 
5.16 ± 
0.55 
7.68 ± 
0.24 
2.59 ± 
0.45 
6.34 ± 
0.42 
 
Discussion 
     This study was performed to find the link between 
obesity, type II diabetes and infertility in males. 
Previous studies showed that ghrelin, a 
gastrointestinal hormone, may be involved in this 
cascade. Ghrelin increases the level of plasma glucose 
and decreases insulin and testosterone levels. 15, 25 This 
study was performed to see the reversal of these 
effects by ghrelin antagonist. We used mice model in 
our study as has previously been used. 15 High fat diet 
with 60% fat was given to induce obesity. Diabetes 
type II and insulin resistance was confirmed in group 
IV and V by fasting blood glucose levels as previously 
described.22 
     Ghrelin is a recently identified potential regulator 
of both energy homeostasis and reproductive function. 
Previous studies show that it has a diabetic like effect, 
increasing blood glucose levels and decreasing plasma 
insulin levels. 15 It interacts with the reproductive axis, 
decreasing plasma testosterone levels. 25 On the other 
hand, Ghrelin antagonist causes a reversal of these 
effects, causing an increase in plasma insulin levels 
and normalizing blood glucose. 26 Our results also 
support the previous studies in animal models where 
ghrelin antagonist decreased blood glucose levels in 
normal and obese mice. 15,16,27  This decrease in blood 
glucose level may be due to an increased secretion of 
insulin promoted by ghrelin antagonist.  Our results 
showed that insulin levels were significantly increased 
in both obese and diabetic groups treated with ghrelin 
antagonist (III and V). The insulin levels were 9.3 % 
more in obese group III compared with obese group II. 
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Similarly blood insulin levels were 5.7 % more in 
diabetic group V compared with group IV. 28 It is 
suggested that ghrelin antagonist enhances the insulin 
secretion by blocking ghrelin receptor thus preventing 
ghrelin inhibitory action on beta cells of pancreas.28 
     Increase in ghrelin is associated with insulin 
resistance. Ghrelin depresses the  expression and 
translocation of glucose transporter type 4 (GLUT 4) in 
muscles causing insulin resistance and ghrelin 
antagonist leads to its improvement as confirmed by 
HOMA-IR measurement. 23 Insulin resistance in 
antagonist treated groups was significantly low 
compared with their respective untreated groups 
(obese group III vs obese group II and diabetic group 
V vs diabetic group IV).Serum ghrelin levels in obese 
subjects are positively related to insulin resistance.29 
The significant reduction in HOMA-IR in our study 
suggests a positive role of ghrelin antagonist in 
normalizing the plasma glucose levels.   
     Previous studies suggest a close association 
between obesity, diabetes and male reproductive 
dysfunctions leading to a decrease production of 
testosterone by the leydig cells. 7, 30 We also showed 
that the levels of testosterone in obese group II, was 
markedly reduced compared with the control. 
Although we did not measure the enzyme activity in 
our study, previous studies show that there is an 
increased activity of enzyme aromatase (involved in 
conversion of testosterone to estrogen) in the adipose 
tissue.31 Enhanced activity of aromatase in obesity 
causes a feedback inhibition of the gonadotrophin-
mediated testosterone secretion.32  Both these effects 
lead to a decrease in testosterone production. 
     Metabolic disturbances like diabetes mellitus also 
lead to impaired reproductive function by disturbing 
the pituitary hypothalamic reproductive axis leading 
to decreased levels of luteinizing hormone, follicular 
stimulating hormone and testosterone.28 In rat model, 
ghrelin significantly decreased the testosterone 
secretion and produced degenerative changes in the 
testis by decreasing the stem cell factor, which 
regulates the development of leydig cells.26 Ghrelin 
has anti-proliferative effects on different testicular cell 
types and is a negative modulator of male 
reproductive system, leading to a decreased 
testosterone production by altering the cellular 
morphology and affecting different cell organelles. 33 
These negative effects of ghrelin on testosterone, 
luteinizing hormone and follicular stimulating 
hormone levels are also seen in humans.18 It is 
suggested that ghrelin negatively modulates the 
hypothalamic-pituitary axis and reduces the pulse 
frequency of gonadotropin-releasing hormone which 
ultimately suppresses levels of luteinizing 
hormone.19,34,35 There is a down regulation of Kiss1 
expression in hypothalamus that in turn decreases the 
pulsatile secretion of LH. 36 Few researchers have 
shown that ghrelin decreases the testosterone 
synthesis by affecting the enzymes involved in 
movement of cholesterol from outer to inner 
mitochondrial membrane or P450cc that is mainly 
involved in conversion of pregnenolone to 
testosterone. 19  
Conclusions 
1.Glucoes level and insulin resistance decrease 
significantly  in  obese and type 2 diabetic mice after 
ghrelin antagonist (D-Lys3) administration  
2.Administration of ghrelin antagonist to obese and 
diabetic groups significantly improves the levels of 
testosterone and luteinizing hormone 
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